annual EBITDA:
$232.90M+$113.20M(+94.58%)Summary
- As of today (July 1, 2025), CPRX annual EBITDA is $232.90 million, with the most recent change of +$113.20 million (+94.58%) on December 31, 2024.
- During the last 3 years, CPRX annual EBITDA has risen by +$180.32 million (+342.97%).
- CPRX annual EBITDA is now at all-time high.
Performance
CPRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$72.83M+$526.00K(+0.73%)Summary
- As of today (July 1, 2025), CPRX quarterly EBITDA is $72.83 million, with the most recent change of +$526.00 thousand (+0.73%) on March 31, 2025.
- Over the past year, CPRX quarterly EBITDA has increased by +$36.27 million (+99.22%).
- CPRX quarterly EBITDA is now at all-time high.
Performance
CPRX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$269.17M+$36.27M(+15.57%)Summary
- As of today (July 1, 2025), CPRX TTM EBITDA is $269.17 million, with the most recent change of +$36.27 million (+15.57%) on March 31, 2025.
- Over the past year, CPRX TTM EBITDA has increased by +$155.13 million (+136.03%).
- CPRX TTM EBITDA is now at all-time high.
Performance
CPRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CPRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +94.6% | +99.2% | +136.0% |
| 3 y3 years | +343.0% | +318.6% | +348.0% |
| 5 y5 years | +630.6% | +575.8% | +526.3% |
CPRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +343.0% | at high | +354.5% | at high | +269.7% |
| 5 y | 5-year | at high | +630.6% | at high | +354.5% | at high | +563.8% |
| alltime | all time | at high | +760.6% | at high | +354.5% | at high | +863.4% |
CPRX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $72.83M(+0.7%) | $269.17M(+15.6%) |
| Dec 2024 | $232.90M(+94.6%) | $72.30M(+19.8%) | $232.90M(+10.2%) |
| Sep 2024 | - | $60.36M(-5.2%) | $211.43M(+72.7%) |
| Jun 2024 | - | $63.68M(+74.2%) | $122.45M(+7.4%) |
| Mar 2024 | - | $36.56M(-28.1%) | $114.04M(-4.7%) |
| Dec 2023 | $119.69M(+16.1%) | $50.84M(-277.6%) | $119.69M(+19.4%) |
| Sep 2023 | - | -$28.62M(-151.8%) | $100.27M(-35.1%) |
| Jun 2023 | - | $55.27M(+30.9%) | $154.55M(+20.8%) |
| Mar 2023 | - | $42.21M(+34.4%) | $127.89M(+24.1%) |
| Dec 2022 | $103.08M(+96.0%) | $31.42M(+22.5%) | $103.08M(+22.1%) |
| Sep 2022 | - | $25.66M(-10.3%) | $84.44M(+16.0%) |
| Jun 2022 | - | $28.61M(+64.4%) | $72.82M(+21.2%) |
| Mar 2022 | - | $17.40M(+36.2%) | $60.08M(+14.3%) |
| Dec 2021 | $52.58M(+27.0%) | $12.78M(-9.0%) | $52.58M(+8.5%) |
| Sep 2021 | - | $14.04M(-11.6%) | $48.44M(+5.0%) |
| Jun 2021 | - | $15.87M(+60.3%) | $46.14M(+13.8%) |
| Mar 2021 | - | $9.90M(+14.6%) | $40.55M(-2.1%) |
| Dec 2020 | $41.40M(+29.9%) | $8.64M(-26.4%) | $41.43M(+1.5%) |
| Sep 2020 | - | $11.73M(+14.1%) | $40.80M(-5.1%) |
| Jun 2020 | - | $10.28M(-4.6%) | $42.98M(-1.7%) |
| Mar 2020 | - | $10.78M(+34.6%) | $43.72M(+36.5%) |
| Dec 2019 | $31.88M(-190.4%) | $8.01M(-42.5%) | $32.03M(+248.4%) |
| Sep 2019 | - | $13.91M(+26.2%) | $9.19M(-171.3%) |
| Jun 2019 | - | $11.03M(-1305.8%) | -$12.89M(-57.4%) |
| Mar 2019 | - | -$914.40K(-93.8%) | -$30.25M(-14.2%) |
| Dec 2018 | -$35.26M(+89.2%) | -$14.83M(+81.5%) | -$35.26M(+36.0%) |
| Sep 2018 | - | -$8.17M(+29.2%) | -$25.93M(+17.6%) |
| Jun 2018 | - | -$6.33M(+6.8%) | -$22.05M(+10.9%) |
| Mar 2018 | - | -$5.93M(+7.6%) | -$19.89M(+6.8%) |
| Dec 2017 | -$18.63M(-3.1%) | -$5.50M(+28.2%) | -$18.63M(+6.9%) |
| Sep 2017 | - | -$4.29M(+3.0%) | -$17.43M(+2.3%) |
| Jun 2017 | - | -$4.17M(-10.7%) | -$17.04M(-3.6%) |
| Mar 2017 | - | -$4.67M(+8.5%) | -$17.68M(-8.1%) |
| Dec 2016 | -$19.24M(-5.5%) | -$4.30M(+10.2%) | -$19.24M(-8.9%) |
| Sep 2016 | - | -$3.90M(-18.8%) | -$21.12M(-5.0%) |
| Jun 2016 | - | -$4.81M(-22.8%) | -$22.22M(-0.4%) |
| Mar 2016 | - | -$6.22M(+0.6%) | -$22.30M(+9.5%) |
| Dec 2015 | -$20.36M | -$6.19M(+23.6%) | -$20.36M(+12.2%) |
| Sep 2015 | - | -$5.01M(+2.4%) | -$18.15M(+5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2015 | - | -$4.89M(+14.1%) | -$17.25M(+12.4%) |
| Mar 2015 | - | -$4.28M(+7.7%) | -$15.35M(+5.4%) |
| Dec 2014 | -$14.56M(+41.6%) | -$3.98M(-3.1%) | -$14.56M(+9.6%) |
| Sep 2014 | - | -$4.10M(+37.5%) | -$13.29M(+6.9%) |
| Jun 2014 | - | -$2.98M(-14.8%) | -$12.43M(+2.8%) |
| Mar 2014 | - | -$3.50M(+29.7%) | -$12.09M(+17.5%) |
| Dec 2013 | -$10.29M(+97.5%) | -$2.70M(-16.6%) | -$10.29M(+13.2%) |
| Sep 2013 | - | -$3.24M(+22.4%) | -$9.09M(+27.5%) |
| Jun 2013 | - | -$2.65M(+55.7%) | -$7.13M(+28.5%) |
| Mar 2013 | - | -$1.70M(+13.1%) | -$5.55M(+6.5%) |
| Dec 2012 | -$5.21M(-13.7%) | -$1.50M(+17.3%) | -$5.21M(-9.1%) |
| Sep 2012 | - | -$1.28M(+20.3%) | -$5.73M(+2.8%) |
| Jun 2012 | - | -$1.06M(-21.8%) | -$5.58M(-5.3%) |
| Mar 2012 | - | -$1.36M(-32.8%) | -$5.89M(-2.5%) |
| Dec 2011 | -$6.04M(+51.0%) | -$2.03M(+80.4%) | -$6.04M(+27.5%) |
| Sep 2011 | - | -$1.12M(-18.4%) | -$4.74M(+4.9%) |
| Jun 2011 | - | -$1.38M(-9.0%) | -$4.52M(+1.1%) |
| Mar 2011 | - | -$1.51M(+108.5%) | -$4.47M(+11.7%) |
| Dec 2010 | -$4.00M(-44.8%) | -$725.70K(-19.6%) | -$4.00M(-9.9%) |
| Sep 2010 | - | -$902.20K(-32.0%) | -$4.44M(-7.9%) |
| Jun 2010 | - | -$1.33M(+27.1%) | -$4.82M(-8.3%) |
| Mar 2010 | - | -$1.04M(-10.2%) | -$5.25M(-27.5%) |
| Dec 2009 | -$7.25M(-33.3%) | -$1.16M(-9.5%) | -$7.25M(-26.6%) |
| Sep 2009 | - | -$1.28M(-27.0%) | -$9.87M(-14.1%) |
| Jun 2009 | - | -$1.76M(-42.0%) | -$11.49M(-5.7%) |
| Mar 2009 | - | -$3.04M(-19.7%) | -$12.18M(+12.2%) |
| Dec 2008 | -$10.86M(+116.7%) | -$3.78M(+30.2%) | -$10.86M(+32.2%) |
| Sep 2008 | - | -$2.91M(+18.4%) | -$8.21M(+31.3%) |
| Jun 2008 | - | -$2.46M(+43.1%) | -$6.25M(+19.5%) |
| Mar 2008 | - | -$1.72M(+51.2%) | -$5.23M(+4.4%) |
| Dec 2007 | -$5.01M(+73.0%) | -$1.13M(+19.8%) | -$5.01M(+5.3%) |
| Sep 2007 | - | -$947.00K(-34.0%) | -$4.76M(-7.6%) |
| Jun 2007 | - | -$1.43M(-4.1%) | -$5.15M(+26.4%) |
| Mar 2007 | - | -$1.50M(+69.1%) | -$4.08M(+57.9%) |
| Dec 2006 | -$2.90M(+59.1%) | -$884.40K(-34.0%) | -$2.58M(+52.1%) |
| Sep 2006 | - | -$1.34M(+275.4%) | -$1.70M(+375.4%) |
| Jun 2006 | - | -$357.00K | -$357.00K |
| Dec 2005 | -$1.82M(+235.6%) | - | - |
| Dec 2004 | -$542.60K(+112.0%) | - | - |
| Dec 2002 | -$255.90K | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual EBITDA year-on-year change?
- What is Catalyst Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Catalyst Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM EBITDA year-on-year change?
What is Catalyst Pharmaceuticals annual EBITDA?
The current annual EBITDA of CPRX is $232.90M
What is the all time high annual EBITDA for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual EBITDA is $232.90M
What is Catalyst Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, CPRX annual EBITDA has changed by +$113.20M (+94.58%)
What is Catalyst Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of CPRX is $72.83M
What is the all time high quarterly EBITDA for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly EBITDA is $72.83M
What is Catalyst Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, CPRX quarterly EBITDA has changed by +$36.27M (+99.22%)
What is Catalyst Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of CPRX is $269.17M
What is the all time high TTM EBITDA for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM EBITDA is $269.17M
What is Catalyst Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, CPRX TTM EBITDA has changed by +$155.13M (+136.03%)